FDA slaps back small-cap's bid to repurpose 50-year-old chemotherapy
When the German drugmaker Medac handed off a decades-old cancer compound to their US subsidiary in February, it thought it would be smooth sailing to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
